Setting new standards in information exchange for the pharmaceutical and biotech industry
The 3rd annual DPharm Europe: Disruptive Innovations to Advance Clinical Trials event was led by Co-Chairs Dr Sue Collier (GSK) and Dr Jeff Kasher (Patients Can’t Wait). The program presented global case studies on:
- Real World Clinical Trial Strategies and Results
- New Leadership in Driving Clinical Trial Innovation
- Strategies to Validate the Siteless Trial
- Community Outreach and Education in Clinical Trials
- New Financial Models
- Patient Involvement and Engagement
- Brexit Update and Potential Impact on R&D
- Protocol Simulation
- Adaptive Trial Model
Highlights for 2017 included:
– New European leadership from big pharma disrupting clinical research
– Community collaborating with industry to disrupt clinical trials
– Real World Data Strategy and Results to disrupt clinical trials
– Making History: the results of crowdfunding the first Clinical Trial and the possibilities for the future of drug development
It was a daunting task to develop the first industry forum on thinking radically different about the way we perform clinical trials, but the result was this conference. The event was first launched in Philadelphia in September 2011 with 125 disruptive thinkers and change makers eager to discuss current solutions in clinical development, propose innovative changes, and commit to testing and sharing the results in order to transform drug development and the industry.
The first DPharm event addressed virtual clinical trial models, adaptive design thinking, the role of EHRs in clinical data, open source, telemedicine, and self-reported patient data among many other ideas.
By the time the 2nd annual DPharm program took place, the concept of applying disruptive thinking to clinical development had taken root, with many attendees bearing titles with clinical innovation in them. Fast forward to current day, we are looking at how new innovations will attract and retain more people in clinical trials, bring down development timelines and figure what data is really useful.
With support from MedCity, the British Consulate and NIHR Clinical Research Network, we look forward to bringing more global examples of disrupting clinical trials and to collaborating on an even broader scale between industry and others.
Not all innovation is disruptive. However, as a global community, we can continue to drive down the cost of drug development and provide better access to clinical trials through innovation, while greatly enhancing the patient experience.
"I thoroughly enjoyed the conference. It was great to hear from such a wide range of knowledgeable speakers and to meet so many like-minded individuals who are enthusiastic about changing the way we do clinical research."
- Sue Collier, GSK
"I really enjoyed the conference and made some useful connections."
- Flóra Raffai, Findacure
"an excellent conference"
- Jane Rhodes, Biogen Idec
"I thoroughly enjoyed DPharm Europe, it was fantastic to see such a huge emphasis on patients and their families at an industry conference!"
- Simon Stones, Generation R
"It was one of the best conferences I have attend in quite some time. The venue, speaker topics, and format had a very light and more personable feel that allowed for learning and networking to be more casual versus other conferences."
- Jen Kelly, HealthiVibe
"Thank you DPharm team: Great content and rich networking opportunities in a really inspiring environment."
- Christian Gossens, Roche Pharmaceuticals